Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 865 | 98 | 762 |
| Samples | 251 | 54 | 192 |
| Peptides | 230 | 38 | 195 |
Function
HLA-G · Major histocompatibility complex, class I, G
HLA-G belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. HLA-G is expressed on fetal derived placental cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domain, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region, and exon 6 encodes the cytoplasmic tail. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000360323 | P17693 | 298 | 197 |
| ENST00000376828 | Q5RJ85* | 261 | 183 |
| ENST00000376818 | P17693-2 | 187 | 129 |
| ENST00000376815 | P17693-3 | 118 | 72 |
| ENST00000615464 | A0A0G2JPQ3* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 197 amino-acid changes on canonical ENST00000360323 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in HLA-G · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in HLA-G – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 3/42 7% | 14/612 2% |
| Cervical Carcinoma | 3/35 9% | 5/422 1% |
| Melanoma | 8/210 4% | 17/1899 1% |
| Colorectal Carcinoma | 6/143 4% | 32/3239 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Glioma | 0/52 0% | 19/2127 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 9/1390 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Neuroendocrine Tumour | 2/154 1% | 3/577 1% |
| Gastric Carcinoma | 0/74 0% | 12/1809 1% |
| Ovarian Carcinoma | 3/109 3% | 4/998 0% |
| Other Solid Cancers | 1/94 1% | 9/1515 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 7/1592 0% |
| Prostate Carcinoma | 1/13 8% | 8/2105 0% |
| Other Sarcomas | 3/69 4% | 0/699 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 8/2534 0% |
| Breast Carcinoma | 4/144 3% | 7/3264 0% |
| Pancreatic Carcinoma | 2/89 2% | 3/1611 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Non-Cancerous | 2/104 2% | 0/830 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 3/2640 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 4/2550 0% |
Mutation Distribution
Where HLA-G is mutated · all tissues, split by cell line vs tissue
How many mutations in HLA-G were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 865 mutations in HLA-G
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|